Actively Recruiting
Evaluating Safety and Efficacy of Inavolisib Combination Therapies in Women With Early-Stage PIK3CA-Mutated Breast Cancer
Led by Hoffmann-La Roche · Updated on 2026-10-26
120
Participants Needed
37
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of inavolisib combination therapies in women with untreated, early-stage Stage II-III, PIK3CA-mutated, estrogen receptor-positive, HER2-negative breast cancer. This Phase II, open-label study focuses on patients suitable for neoadjuvant endocrine combination therapy and aims to better understand treatment options for this specific breast cancer subtype. Participants will be assigned randomly to different treatment groups where they will receive various combinations of oral inavolisib, letrozole, ribociclib, and giredestrant. Treatments are given in cycles, with initial cycles lasting 28 days, followed by a shorter 21-day cycle, adjusting the combination doses accordingly. The study includes multiple experimental arms, each with a specific regimen schedule over approximately six cycles. Throughout the study, participants will undergo regular assessments including monitoring of adverse events, tumor response evaluations, and biomarker changes such as Ki-67 levels. Patient-reported outcomes related to symptoms and treatment side effects will also be collected. Safety is tracked up to 30 days after the last dose, with the entire participation lasting about eight months to cover treatment and evaluation periods.
CONDITIONS
Brief Title
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
Research Team
R
Reference Study ID Number: BO45853 https://forpatients.roche.com/ No attachments to email below.
F
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here